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Abstract
Lactoferrin is an iron-binding glycoprotein of the innate immune system, which is
present in some mammalian fluids and secreted into the mucosae; it is also produced
by the secondary granules of the polymorphonuclear neutrophils and secreted at infec-
tion sites. Lactoferricins (Lfcins) are peptides derived from the N-terminus of Lf. Lf
avoids the iron availability to parasites in the body fluids due to its high avidity for iron,
maintaining together with transferrin the free-iron concentration in about 10−18 M,
which is too low to support the pathogenic invader survival. Intestinal parasitic diseases
affect people worldwide, mainly in developing countries with poor hygienic conditions;
for example, parasites such as Entamoeba histolytica, Giardia intestinalis, and Cryptosporid-
ium parvum infect the human intestine when are orally ingested as cysts. Human and
bovine Lf have been found parasiticidal in experiments in vitro and in animal models.
Interestingly, Lf synergizes with metronidazole, the main drug used against E. histolytica
and G. intestinalis. The aim of this chapter is to show the benefits of using Lf and Lfcins
against intestinal parasitic diseases.
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1. Introduction
Lactoferrin (Lf) is an iron-binding nonheme glycoprotein that possesses an exceptional high
iron-binding affinity and retains iron at acidic pH. Lf is mainly devoted to chelate iron in fluids
and secretions; in addition, Lf is immunomodulatory. Based on its iron content, Lf can exist in
two forms: iron-loaded (holoLf, with one or two ferric ions) and iron-free (apoLf). Lf is a
constituent of the mammalian innate-immune defense system. In mucosae, Lf displays antimi-
crobial activity against a wide range of pathogens [1–5]. Lf is synthesized by the mammary
gland and secreted into colostrum and milk, participating in the primary immune response
in newborns [5–8]. In humans, Lf concentration ranges from 7 to 15 mg/ml in colostrum and
1.2 mg/ml in mature milk. Lf is also present in tears, saliva, and exocrine secretions of mucosal
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surfaces located in the respiratory, reproductive, and intestinal tracts [9–12]. Lf has been found
in tissues of the stomach, lung, liver, bone marrow, cartilage, and bones [13–16]. In the
gastrointestinal tract, Lf concentration varies from 0.75 μg/ml in duodenal juice, 0.71–1.07 μg/ml
in whole gut lavage fluid, or 0.3–0.7 μg/g in feces [17].
Lf is also synthesized during the transition from promyelocytes to myelocytes of white cells;
thus it is a major component of the secondary granules of polymorphonuclear (PMN) neutro-
phils present in blood [18]. These cells store Lf (3 μg Lf/106 neutrophils) and they release it at
the sites of microbial invasion which are of low pH due to the pathogens activity [2, 7, 11, 19].
Lf concentration in plasma is relatively low (0.0004–0.002 mg/ml) and derives from neutro-
phils; however, in patients with sepsis neutrophils are activated and degranulated, secreting
into the bloodstream significant levels of apoLf (~0.2 mg/ml) [9]. Lf in feces is also due to the
neutrophils action and its concentration noticeably increases in bowel inflammatory diseases
(BID) due to pathogenic bacteria, such as ulcerative colitis and Crohn’s disease. Thus, Lf is
used in a test as an inflammatory marker in intestine, test that discriminates between people
suffering BID from those that only have irritable bowel syndrome (IBS), who show normal
values of Lf [20]. A test of latex agglutination using anti-Lf antibodies demonstrated that cases
with either shigellosis or bacterial urinary infections revealed a high Lf titer which was posi-
tively correlated with the number of PMN. In contrast, cases with parasitic infections such as
Entamoeba histolytica or Schistosoma haematobium were characterized by a relatively lower
inflammatory process as expressed by mild Lf titer which was also correlated with the PMN
count [21]. Ascites Lf can also offer a promising biomarker for bacterial peritonitis, and Lf in
pancreatic juice and stone could provide pathophysiological information [22].
2. Structure and biological properties of lactoferrin
Lf was initially identified from bovine milk [23], and simultaneously isolated from bovine [24]
and human [25] milk more than 55 years ago. Both glycoproteins (hLf and bLf) share 70% in
amino acid sequence [26] and are monomeric, with an approximated molecular weight of
80 kDa; both are highly cationic with a basic isoelectric point (8.5–9). Tertiary structure of Lf
consists in two main N and C lobes that are in turn organized in domains N1, N2, and C1 and
C2. Both lobes are linked at N1 and C1 domains by a three-turn alpha chain [27, 28] and are
able to bind one ferric ion (Kd = 10−23 M); this ion derives from the diet or from iron-charged
transferrin (holoTf) [29]; Tf is a similar glycoprotein present in plasma and lymph but it has
lower affinity for iron than Lf. HoloLf structure is conformationally more rigid and stable
compared with apoLf [30–32].
In the N1 terminus of Lf, there is a region lacking iron-chelating activity, known as a
lactoferricin (Lfcin) domain, characterized by its strong cationic charge. Lfcin can be obtained
from Lf by enzymatic proteolysis with stomach pepsin; the antibacterial properties of Lf are
due to this Lfcin domain [33–35]. Several Lfcins have been employed against pathogens, and
they are termed according to the residues number they contain. Moreover, antimicrobial
peptides have been synthesized and can be used in combination with drugs [36]. Synthetic
Lfcin17-30 and lactoferrampin (Lfampin265-284), and a fusion peptide of both, Lfchimera,
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have been assayed against multiresistant bacteria, and also those that form biofilms [37–39].
Lfchimera also has been tested against parasitic protozoa [40–42].
Microbes that colonize mucosal surfaces in the different body tracts will likely be exposed to
different concentrations of Lf, to different complexes of Lf with other proteins, and to different
levels of Lf derivatives [43]. As a plus of the beneficial effects of Lf in the intestinal tissues,
many studies report its property as growth-promoting on bifidobacteria [44]. All these find-
ings suggest that Lf and Lfcins can be of potential use as adjuncts to conventional antibiotics
and drugs in the pharmacological use against pathogens.
3. Importance of iron in infections and the role of lactoferrin
Due to the iron toxicity, all organisms need to regulate its concentration and maintain iron
homeostasis [45, 46]. This transition element is mainly linked to proteins, like the heme group
in hemoglobin, as cofactor of enzymes, bound to other proteins like iron-chelating proteins, or
stored in ferritin [9, 45, 47, 48].
To multiply and cause disease, parasites must acquire iron within their vertebrate hosts.
However, mammals have evolved a universal strategy against microbial invaders, consisting
in the expression of iron-sequestering systems for dropping the free iron concentration that
pathogens need to survive inside a host. The iron-chelating property of Lf and Tf in fluids
leads to a concentration of 10−18 M, a quantity too low to sustain the microbial life [9, 49, 50]. In
addition, infections are often associated with a reduction in the circulating iron in fluids, a host
response known as hypoferremia of infection [10]. So, pathogens must have systems needed to
gain the iron retained in human proteins such as Lf; if not, they succumb by the iron restriction.
This is the reason by which Lf is microbiostatic.
Furthermore, Lf can damage the functional integrity of the microbial surface and being bacte-
ricide [1]; diverse authors have shown that bLf and hLf display activity against Gram-positive
and Gram-negative bacteria, including antibiotic multiresistant bacteria [35, 51–53]. Lf is also
able to affect and kill certain unicellular parasites, such as Toxoplasma, Entamoeba, and Giardia.
In consequence, Lf can be parasiticide [54–56].
On the other hand, Lf is considered a modulatory molecule of both the innate and adaptive
immune systems. Lf is able to modify the production of humoral mediators and the activity
of cell components involved in specific immune responses, such as the increase of T-cell
proliferation and maturation [57–60]. Lf is capable of modulating the response of macro-
phages to induce a Th1 response essential to combat intracellular pathogens [61–64]. Effects
of Lf on inflammation correlate with a decrease of the proinflammatory mediator tumor
necrosis factor (TNF), interleukin (IL)-6, and IL-1 and, in some cases, with an increase of
anti-inflammatory interleukins, IL-4 and IL-10 [65–68]. Lf from neutrophils decreases the
TNF release and modulates the recruitment and activation of phagocytes to sites of inflam-
mation. Also the peptide Lfcin has shown anti-inflammatory effect [69]. In addition, several
researchers have proven that orally administrated bLf prevents cancer progression, which
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could be due to an improvement of immunity against the tumor cells, or a direct interaction
with these cells, or to both effects [16, 70].
4. Lactoferrin against intestinal infections caused by parasites
The identification of natural compounds with antiparasitic activity has always been a pivotal
aim of parasitology research. Alternative therapies against parasites have been explored
mainly in chronic infections, or when drugs cause adverse effects, or when microbes are
resistant to all treatments. As a consequence to be part of the mammalian natural defense, Lf
has been searched as an antimicrobial in assays in vitro, and a minimal inhibitory concentration
(MIC) has been established for each microorganism tested. Experimental infections have also
been performed in vivo in animal models in which different doses of Lf and administration via
have been employed, and the reduction of lesions is evidenced. In a wide range of bacteria and
in less number of fungi and parasites, Lf has been tested as microbicide, in some cases with
promissory results. It has been shown that Lf inhibits the growth of protozoan parasites, such
as Toxoplasma gondii [55], Plasmodium falciparum [71], Trypanosoma cruzi [72], and E. histolytica
[73, 74]. T. cruzi is an emerging parasite responsible for frequent outbreaks of acute cases of
Chagas disease contracted orally and causing high mortality [75]. In this chapter, the interac-
tions of some intestinal protozoa with the innate immune-system protein Lf are discussed, as
examples of the Lf parasiticidal action. Table 1 shows the cases of parasites affected by Lf and
its natural or synthetic derived peptides.
4.1. Entamoeba histolytica and amoebiasis
Amoebiasis is a parasitic disease caused by the protozoan E. histolytica and a major medical
problem in developing countries. This infection is responsible for 50 million cases of tissue
invasion and 60,000 deaths per year [76]. Amoebiasis is primarily spread in food and water
contaminated by human feces [77, 78]. Only about 10% people show invasive symptoms and
the rest of them can remain asymptomatic due to the host defense. In addition, Entamoeba
dispar, a morphologically indistinguishable noninvasive amoeba, is involved in many asymp-
tomatic cases. Distinguishing E. histolytica from E. dispar requires molecular or enzymatic
characterization [79].
Furthermore, the pattern of amoebic infection, the presence of antibodies, manifestations of
disease, an approach to investigations, and strategies for management remain complex [80].
E. histolytica trophozoites (amoebae) can damage the large intestine causing ulcers and some-
times they move to the liver, forming abscesses that could be fatal if not treated. E. histolytica
can also affect nonhuman primates in captivity or wild life [81, 82]. The in vitro studies of
amoebic pathogenesis have demonstrated three essential processes in the interaction of
E. histolytica with target cells: (1) adherence of amoebae to cells, which is mediated in virulent
strains by a GalNAc-inhibitable amoebic adhesin; (2) contact-dependent target cell lysis, and
(3) amoebic phagocytosis of target cells [83, 84]. Many factors have been involved in promoting
the invasiveness, pathogenicity, and virulence of E. histolytica [85].
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Noteworthy, incidence of amoebiasis remains high nowadays when compared to the last
century, in spite of the high efficacy of metronidazole treatment. However, this drug causes
nausea, vomiting, and other side effects, in addition to be found mutagenic in bacterial
cultures, and carcinogenic to experimental animal models [86, 87]. These findings, and the
obtaining of resistant strains to metronidazole in vitro, encourage us to the development and/
Parasite Protein and/or peptides Experiments performed References
Amoebozoa
Entamoeba
histolytica
hLf bLF Lfcin4-14 LFcin17-
30 LFampin265-284
LFchimera
In vitro assays Viability assays; E. histolytica trophozoites
were incubated with the Lfs or peptides.Viability was
established.Also, synergy of Lf with metronidazole was
assayed.
[40, 73, 74]
bLF In vivoMurine intestinal amoebiasis model;Mice were
intracecal inoculated with E. histolytica trophozoites, and
then intestinal amoebiasis was developed. bLF was
orally administered. Viability and infection of mice was
determined.
[99]
bLF In vivoAmoebic liver abscess; mice were intraportal
inoculated with E. histolytica trophozoites until liver
abscess development, and then hepatic amoebiasis was
developed. hLF was orally administered.Viability and
infection of mice was determined.
[108]
Metamonada
Giardia intestinalis
hLf bLf Lfcin4-14 In vitro assays Viability assays; G. intestinalis cultures
were incubated with hLf, bLF, and natural Lfcins.
Viability was assessed.
[54]
bLF LFcin17-30
LFampin265-284
LFchimera
In vitro assays Viability assays, clinical isolates of G.
intestinalis were incubated with bLF and the synthetic
bLF derived peptides.Viability of cultures was
determined.
[42]
bLf Clinical trials bLF versus placebo were administered to
children for the prevention of diarrhea by G. intestinalis.
[103]
Apicomplexa
Cryptosporidium
parvum
hLf bLf hLfcin bLfcin Infectivity assay on host cell cultures Preincubation of
sporozoites with Lf or peptides and then, infection of
Caco-2 cells.
[135]
Microsporidia
Encephalitozoon
intestinalis
hLf bLfcin4-14 Spore germination assay on host cell cultures Intestinal
epithelial cells were infected with clinical isolates of E.
intestinalis and then, were treated with hLf or bLFcin4-14.
[143]
Fungi Candida
albicans
pLf In vivo assay Oral administration with porcine Lf-rich
milk in mice pups infected with C. albicans
[147]
Apicomplexa
Toxoplasma gondii
bLF Lfcin In vitro assays Viability assays; T. gondii was incubated
with the Lfs or peptides. Viability and infectivity
established. In vivo assays Infection of mice and
pretreated or treated with bLF administered orally.
Infectivity, parasitemia, and survival of mice were
determined.
[148, 149]
[150, 151]
Helminths
Haemonchus
contortus
cLf In vitro assays Effect of cLf on egg hatching and worm
motility inhibition
[152]
Table 1. Parasites affected by lactoferrin and its natural or synthetic derived peptides.
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or identification of new antiamoebic drugs that could replace metronidazole or synergize
with it allowing a diminution in the dose of drug necessary for an effective treatment [88–
90]. Up to date, there is no direct evidence of a protective role of Lf in human intestinal and
hepatic amoebiasis. However, results from studies in vitro and in experimental animal
models allow us to consider the use of Lf for both types of amoebiasis.
4.1.1. Studies in vitro of use of lactoferrin against E. histolytica trophozoite growth
Our group of research fractionated human milk and tested each fraction against amoebae in an
axenic culture to search an effect of Lf, lysozyme, and secretory immunoglobulin A (sIgA); we
also sought any combined effect among these molecules, and tested human, bovine, and swine
milk against the parasite. For that, trophozoites of the strain HM-1:IMSS were treated with
5–20% of each milk, with 10% of human milk fractions, or with 1 mg/ml of isolated human
milk Lf or sIgA, or chicken egg white lysozyme. From milks, only human and bovine milk
were amoebicidal showing a concentration-dependent effect, which increased in the absence of
iron. Human milk protein fractions (Lf, lysozyme, and sIgA) were amoebicidal, and Lf showed
the major effect [74]. Regarding the mechanism of action, Lf bound to the amoebic membrane
causing cell rounding, lipid disruption, and damage.
In another work, the microbicidal action of hLf, bLf, and Lfcin4-14 was established on the
viability of E. histolytica trophozoites. Both Lfs and Lfcin were able to kill amoebae in a
concentration-dependent manner. The effect was modulated according to the culture age,
pH, and temperature and prevented by Fe2+ and Fe3+. Mg2+ and Ca2+ prevented the killing
effect of Lf but not of Lfcin. Parasites obtained from the stationary phase were more suscep-
tible to Lf than those from the exponential phase. A synergistic effect was observed with
metronidazole, decreasing about fivefold the concentration necessary to kill most amoebae
[73, 74]. This observation is important, since as we mentioned before, metronidazole has
been found toxic and mutagenic at the used concentrations. These data suggest that both Lfs
and bLfcin might be used in amoebiasis if they are administered with low doses of metroni-
dazole to have less toxicity of this drug. After that, we used the synthetic peptides Lfcin17-
30, Lfampin256-284, and Lfchimera to search for an effect against E. histolytica. At 50 μM of
each peptide, Lfcin and Lfampin showed a moderate amoebicidal effect, with 45–50% of
amoeba viable at 24 h culture. However, at 50 μM Lfchimera, about 75% of amoebae were
killed, whereas at 100 μM all parasites died. These data indicate that N-terminal Lf-peptides,
mainly Lfchimera, have amoebicidal activity in a time- and concentration-dependent man-
ner [40].
4.1.2. Effect of lactoferrin on a murine intestinal-amoebiasis model
Infection with E. histolytica may be confined to the intestinal lumen, or can result in invasion
of the colonic mucosa (intestinal amoebiasis, IA). Pathologic changes of this mucosa initially
are nonspecific but are followed by ulceration [77]. In a study with 3000 patients, it was
found that the clinic-pathologic forms of the disease were: ulcerative rectocolitis (95%),
typhloappendicitis (3%), amoeboma (1.5%), and fulminating colitis with toxic megacolon
(0.5%) [91].
Natural Remedies in the Fight Against Parasites160
In addition to the studies in vitro, human breast milk and saliva secretions have been well
documented to possess antiamoebic activity and, in addition to the sIgA antibodies, Lf could
be one of the active molecules in IA [92–95]. Around 35 years ago, it was suggested that Lf
present in milk could be involved in protecting against IA in some population groups. Pro-
spective studies carried out on Turkana and Maasai African nomads that consume milk as the
major item in their diet showed amoeba seronegativity or freedom from intestinal infection
with E. histolytica, respectively, in contrast to similar nomads having a mixed diet. In both
studies, the milk-drinker group showed iron deficiency, probably due to the poor supply of
iron in the milk, and it was proposed that the low intestinal content of iron affected the growth
of E. histolytica. Noteworthy, it was also proposed that Lf and Tf present in the milk may
actively compete with amoeba for intestinal iron [92, 96]. Likewise, newborns are protected
against infectious agents including amoeba while they are being breastfed. In a study carried
out with 322 Egyptian infants of 2–6 months old, the group who had been breastfed since birth
showed significantly lower incidence of parasitic infections than the other group who only
received formula (38.5% versus 75.2%, respectively). Reduction in infections by Cryptosporidium
spp., E. histolytica/E. dispar, G. lamblia, and Blastocystis spp., as well as mixed parasite infections,
was observed. These studies suggested that cattle and breast milk contain components that can
combat intestinal infections in humans [97].
In contrast to the well-documented antiamoebic potential of Lf in vitro, almost nothing is
known about its effect on an intestinal model of infection. The only study of this type has been
addressed by our group in a murine model of cecal amoebiasis with high success [98]. The
model uses mice of the C3H/HeJ strain, which has a spontaneous mutation in the toll-like
receptor 4 gene, Tlr4Lps-d, making these mice more resistant to endotoxin. Intracecal inocula-
tion with virulent E. histolytica cultured trophozoites results in an inflammatory and ulcerative
disease highly reminiscent of human IA, starting with tiny erosions of the surface epithelium at
5 days, which evolve to deeper and extensive destructive lesions of the cecal wall at 21 days,
including flask-shaped ulcers, intestinal perforations, and intramural abscesses formation,
without evidence of tissue invasion by amoebae. In this model, we found that a simple oral
dose of bLf to mice controls the infection already established in the cecum [99]. Details of this
experiment are included below paragraphs.
Germ-free mice of the C3H/HeJ strain were intracecally infected by 106 virulent amoebae
(strain HM1:IMSS). Fourteen days post challenge, by which time amoeba-induced lesions
are expected [98], a group of mice was orally treated with bLf (20 mg/kg), daily for 7 days. At
21 days, all mice were sacrificed and the ceca exscinded, fixed, and embedded in paraffin
(Figure 1, upper cartoon). Finally, tissue sections were stained with hematoxylin-eosin for
histological analysis. The results showed that infected mice receiving bLf cured IA in 63.14%
as neither trophozoites nor tissue damage were found in sections of the ceca (Figure 1A). The
rest of treated mice showed partial resolve of the infection, evidenced by reduction in the
number of amoebae and tissue damage, compared with the untreated mice, which had
inflamed and vascularized ceca with abundant mucus, amoebae, and microhemorrhages
(Figure 1B). Intriguingly, a similar protocol of treatment with 200 mg/kg did not resolve the
infection, which could be due to the formation of immune complexes between bLf and sIgA
antibodies present in the intestinal lumen, and/or formation of anionic aggregates that occur
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when high amounts of Lf are prepared in high salt concentrations [100]. It is worthy of noting
that resolution of the IA by bLf correlated both with an increased production of total sIgA and
an anti-inflammatory response, determined in cecum tissue extracts or tissue sections, respec-
tively. The average of total sIgA levels in cured mice was twofold higher than that observed in
the infected ones, and also higher in completely cured mice when compared to sIgA levels in
mice with partial resolution of the infection. Also, whereas high expression of proinflammatory
INFγ and TNFα as well as of regulatory IL-10 and TGFβ cytokines were observed in the ceca of
infected mice, only high expression of IL-4 was observed in the bLf treated and cured mice. The
immune-regulatory activity of Lf has been well documented, mainly downregulating the inflam-
matory response and reestablishing intestinal homeostasis, but also upregulating the humoral
response [101, 102].
In conclusion, Lf might exert a protective effect against IA, through multiple mechanisms
because of its multifaceted properties. Directly, Lf may perform amoebicidal activity
disrupting the parasite membrane as suggested from the in vitro studies. Indirectly, Lf may
boost the intestinal secretory immune response increasing the production of both, unspecific
and specific antiamoeba IgA antibodies that could block the adherence of amoebae to the gut
epithelium, or inhibit the growth of parasites by competing for local iron. Based on our studies
aforementioned, and that the therapeutic use of Lf for treating infections causing diarrhea in
humans is highly safe [103, 104], we suggest that oral daily treatment with a relatively low
Figure 1. Treatment protocol with bLf against intestinal amoebiasis in a murine model. Above: Mice strain C3H/HeJ was
intracecally infected with virulent E. histolytica trophozoites. Two weeks post-infection, mice were treated daily by oral
route with 20 mg/kg bLf for 1 week. Upon completion of treatment, the mice were sacrificed and the ceca processed for
histological analysis. Below: The treated mice showed absence of infection (left tissue section) compared to the ceca of
infected but untreated mice (right tissue section), which showed many trophozoites in the lumen (arrows) and extensive
damage of the intestinal epithelium, with loss of epithelial integrity (arrow head) and micro-hemorrhages (asterisk).
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dose of bLf for 1 week, either alone or in combination with metronidazole, could represent a
new therapeutic strategy for curing the human intestinal infection caused by E. histolytica.
4.1.3. Effect of lactoferrin on the amoebic liver abscess
Intestinal amoebiasis may complicate by spreading of amoebae via the portal venous to the
liver, or perforation of the intestinal wall, resulting in peritonitis or fistulas. Amoebic liver
abscesses (ALA) may perforate into the peritoneal, pleural, or pericardial cavities. Hematoge-
nous spreading of amoebae can also result in abscess formation in more distant sites, such as
the brain [105]. ALA is the most important for no intestinal infection, due to its high frequency
of occurrence and serious clinical concerns, since ALA occurs in up to 95% of fatal cases of
amoebiasis. The abscess is composed of a thin capsular wall whose inner surface has “shaggy”
appearance; microscopically, the abscess fluid is granular with eosinophilic debris and few or
no cells. Smaller abscesses have been felt by some authors to form larger abscesses by coales-
cence; portal fibrosis and bile duct proliferation have been noted as part of a healing process
[106].
ALA can be induced in animal models by intraportal inoculation of amoebae, and it presents a
PMN infiltrate within the first 12 hours. As the neutrophils and hepatocytes lyse, the amoebae
remain in debris of basophilic material. Later in the progression of abscess formation, these
form a more organized capsule with collagen fibers and fibroblasts surrounded by macro-
phages and epithelioid cells. Experimental amoebiasis has been conducted to evaluate thera-
peutic regimens, immunology, or pathology of invasive amoebiasis [106, 107]. In this sense, we
evaluated the therapeutic effect of bLf in a model of ALA in hamsters. Interestingly, hamsters
treated intragastrically with Lf (2.5 mg/100 g body weight) over a period of 8 days, showed no
clinical signs of disease and ALAwas effectively decreased with only 0.63% detectable lesion,
compared with 63% in untreated animals. Furthermore, liver function and blood cells
approached normal levels in hamsters receiving bLf treatment [108]. These results suggest that
bLf may aid in the therapy of amoebiasis, most likely without producing side effects in
patients.
4.2. Giardia intestinalis
Giardia intestinalis (also known as Giardia lamblia or Giardia duodenalis) is a flagellated unicellu-
lar binucleated parasite that causes giardiasis, a diarrheal disease spread throughout the world
[109]. Giardiasis is the most common cause of waterborne outbreaks of diarrhea. The preva-
lence of this parasitic disease commonly ranges from 20 to 30% of the population in developing
countries or 3 to 7% in developed ones. Giardiasis is reported more frequently in young
children (between 6 months and 5 years of age), and in chronically infected and immune-
suppressed people, and also in susceptible travelers [109, 110].
Giardia species have two major stages in their lifecycle. First, infection with G. intestinalis initiates
when the cysts are ingested in contaminated water or, less commonly, foods. The cyst is rela-
tively inert, allowing prolonged survival in a variety of environmental conditions. Cysts excyst
into trophozoites in the proximal small intestine, and then they attach to the lining of the small
intestine and reproduce, interfering with the absorption of fats and carbohydrates from digested
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foods, causing diarrhea and malabsorption [111]. After exposure to biliary fluid, some trophozo-
ites form cysts in the jejunum and pass to the feces, allowing for completion the transmission
cycle by infecting a new host [112, 113]. When the clinical signs of infection are present, they may
include diarrhea, nausea, weight loss, and abdominal pain. Giardiasis is an established cause of
failure to thrive in children; it also causes diminished cognitive functions and chronic fatigue. In
adults, giardiasis may lead to postinfectious gastrointestinal disorders such as IBS and dyspep-
sia. In addition to diarrhea, G. intestinalis causes iron deficiency anemia, micronutrient deficien-
cies, protein-energy malnutrition, growth and cognitive retardation, and malabsorption. A few
cases of Giardia associated with tumor masses have also been reported, but cause-to-effect
relationship between giardiasis and cancer has yet to be established [114].
When giardiasis develops symptoms, a standard treatment mainly consists of metronidazole
therapy. However, in addition to this drug causes side effects in patients, it has been associated
with significant failure rates in clearing parasites from the gut [109]. Also, an increasing
incidence of nitroimidazole-refractory giardiasis has been reported in travelers from India
[115]. A correct fluid and electrolyte management is critical, mainly [22] in patients with
large-volume diarrheal losses, and children with acute or chronic diarrhea in whom Giardia
organisms have been identified [116–118]. In some patients, giardiasis resolves within a few
days, whereas in others the symptoms last for years, even in the presence of circulating
antigiardia antibodies in serum, or sIgA antibodies at mucosal sites and the cell-mediated
immunity. Because of its biological features, it is likely that nonimmune factors play a role in
the susceptibility or duration and severity of the disease. Both humoral and cell-mediated
immune responses play a role in giardiasis, but the mechanisms involved are poorly known
[119]. For example, human milk kills G. duodenalis trophozoites independently of specific sIgA
antibodies [120]. The giardicidal factors present in milk are conjugated bile salts and unsatu-
rated and free fatty acids [121–124]. Also, human neutrophil defensins and indolicidin were
giardicides when they were added to the culture medium [111, 125].
It has been tested the effect of hLf, bLf, hLfcin, and bLfcin against G. intestinalis, in vitro [54].
On a molar basis, bLfcin had the most potent giardicidal activity, followed by hLfcin, bLf,
and hLf; this effect was concentration-dependent and the activity estimated during 2 h of
incubation. In addition, trophozoites from early stationary phase cultures were more sus-
ceptible to the parasiticidal effect. Intestinal factors and physiologic conditions present in the
intestine did not have effect on the activity exhibited by Lfs and Lfcins. On the other hand,
MgCl2, CaCl2, and CoCl2 protected against the activity of hLf and bLf, but not of Lfcins
against G. intestinalis. In the presence of ferric iron, neither Lfs nor Lfcins presented parasiticidal
activity, indicating that iron has protective effects [54]. This finding is interesting, since Lfcins did
not have any site for iron binding. Under electron microscopy, it was detected that giardias
treated with Lfs and Lfcins showed striking and complexmorphologic changes in plasmalemma,
endomembrane, and cytoskeleton, and increased the electron density of lysosome-like peripheral
vacuoles. Also, it was observed by confocal microscopy that Lfs and Lfcins are able to be bound
by G. intestinalismembranes [126].
Recently, the effect of synthetic bovine Lfcins on the growth of G. intestinalis culture was
studied. The peptides Lfcin17-30 and Lfampin265-284 and the fusion of both Lfchimera
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showed microbicidal activity against G. intestinalis trophozoites. Apparently, the best effect
was exerted by Lfchimera, since the first hour of incubation. Additionally, low concentrations
of this peptide combined with low concentrations of metronidazole or albendazole had a
better effect on the inhibition of G. intestinalis cultures than the drugs or peptides used alone.
When the mechanism of action was explored by transmission and scanning electron micros-
copy, trophozoites treated with the synthetic Lfcins showed damage on membrane and inter-
nal structures [42].
The effect of bovine Lf has been also tested in patients. A randomized, double-blind, placebo-
controlled trial was conducted, in a supplementation with bLf (0.5 g twice daily for 9 months),
for the prevention of diarrhea in 26 children of 12–36 months of age, in Peru. In the comparison
of results, the overall diarrhea incidence and prevalence rates were similar between the two
groups (the Lf group versus the placebo group). However, there was a lower prevalence of
colonization with Giardia species and better growth among children in the Lf group [103]. In
conclusion, data from experiments in vitro and those from patients support the idea that Lf and
Lfcins can be used in the defense against giardiasis.
4.3. Cryptosporidium parvum
Cryptosporidium parvum is an apicomplexan parasite of human and veterinary importance that
causes diarrhea and gastroenteritis. Infection is common in children of developing countries
with poor hygiene practices and no potable water supplies, where it has high seroprevalence
rates and specific IgG seropositivity after 1 year of age, with recurrent infections and relapsing
diarrhea [127–129]. The main risk factors are the ingestion of contaminated water, contact with
infected persons or animals, and travel to endemic areas of the disease. The Cryptosporidium
life cycle is divided into six major developmental phases; the infective sporozoites are pro-
duced after excystation of oocysts [130] that attach to the cell apical surfaces and become
internalized within an intracellular but extra-cytoplasmic compartment, which is separated
from the cytoplasm by an electron-dense layer that appears to be predominantly of host origin.
In this compartment, parasite is protected from the hostile gut environment and supplied with
energy and nutrients by the host cell through a feeder organelle, which is unique among
apicomplexan parasites [131]. It has also been reported that C. parvum may have extracellular
gregarine-like life stages [132].
In immunocompetent patients, diarrhea due to C. parvum is self-limited; however, cryptospo-
ridiosis is recognized as an important disease in immunosuppressed people such as AIDS
patients. By immunological and molecular techniques, researchers have identified over 25
putative virulence factors, which are proposed to be involved in aspects of host-pathogen
interactions from adhesion and locomotion to invasion and proliferation [131, 133]. It has been
investigated the increase of Lf in feces as an indicator of inflammation in healthy adult
volunteers experimentally infected with oocysts, and in children with diarrhea that have
naturally acquired C. parvum. Of the 21 specimens taken post challenge, only one of 14
Cryptosporidium-seropositive patients had Lf titer >1:50. In contrast, 12 of 17 specimens from
children with only Cryptosporidium infection had mild to moderate elevation of fecal Lf. These
results suggest that there may be a mild subclinical inflammatory component in
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cryptosporidiosis in children with diarrhea. Also, that Lf increase is a good tool to detect
inflammation in cryptosporidiosis [134].
Currently, there are no consistently effective parasite-specific pharmaceuticals or immunother-
apies for control of cryptosporidiosis. Thus, several alternative therapies have been studied to
combat this disease, among them, some natural compounds from the innate immune system.
Some in vitro assays have been performed to demonstrate whether bLf, bLfcin, and a bLf
pepsin hydrolysate (bLfh) have some effect against C. parvum. For that, freshly excysted
sporozoites were incubated for 15 min in MEM containing 10 μg/ml of Lf or its derivative
peptides; further, an infection to Caco-2 cells was done. The authors found that only the bLfh
and bLfcin were highly parasiticidal decreasing sporozoite viability by 45–69% when com-
pared to the control. In addition, these compounds strongly reduced sporozoite infectivity to
the cells. The viability percentage was similar when the bLfh and bLfcin were used [135]. From
these experiments, we can deduce that it would be remarkable the use of bLf derivatives to
prevent or cure the infection by C. parvum.
4.4. Fungi
4.4.1. Microsporidia
Microsporidia are unicellular, obligate intracellular fungal parasites that affect a variety of
vertebrate and invertebrate hosts. The phylum Microsporidia comprises 150 genera with more
than 1200 species, fromwhich only seven genera infect humans [136]. These parasites have been
found in water sources and in wild, domestic, laboratory, and food-producing farm animals;
thus, microsporidia can also cause zoonotic diseases. In addition, microsporidiosis is an emer-
gent infection because the parasites are opportunistic agents in patients with HIV, or in those
immunosuppressed by organ transplant, or in children and old people, affecting the gastroin-
testinal tract, nasopharynx, lungs, eyes, and skin [136, 137]. In the gastrointestinal tract, infec-
tion of differentiated mucosal epithelial cells most likely results from impalement via spores
containing a unique coiled tube used to impale target cells and inject the infectious sporoplasm
[138]. Spores germinate in the lumen in close proximity to the target cells [136, 139, 140]. In
addition to the unique way in which microsporidia infect cells, Encephalitozoon cuniculi spores
enter nonprofessional phagocytes by phagocytosis and traffic into a late endosomal-lysosomal
compartment; after being phagocytosed, spores germinate within the cell [141, 142]. The path-
ogenesis of intestinal disease is related to excess death of enterocytes as a result of cellular
infection. Clinically, microsporidiosis most often presents with diarrhea and weight loss as a
result of small intestinal injury and malabsorption [140]. Enterocytozoon bieneusi is the most
common microsporidial cause of human intestinal disease. A second species, Encephalitozoon
intestinalis (originally named Septata intestinalis) is associated with disseminated as well as
intestinal disease, and the second most common cause of intestinal microsporidiosis. Therapeu-
tic options are few; E. intestinalis responds well to albendazole, whereas no antiparasitic therapy
has documented efficacy in E. bieneusi infections [140].
Leitch and Ceballos [143] [E-CE3] studied clinical isolates of E. intestinalis. A spore germination
assay and a cultured intestinal epithelial cell-infection assay were used to determine if hLf and
bLfcin, in addition to lysozyme and defensins, could inhibit the infection. In this assay, cells
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were cultured on collagen-coated chamber slides, and at 7 days post confluence, monolayers
were infected with 4 + 10
5 spores per well. After 24 hours p.i., the excess of spores was
removed with Opti-MEM containing 1 mg/ml chondroitin sulfate and the wells refilled with
medium. At 3 days p.i., cells were fixed and stained to visualize parasite sporogonial stages
[144] and detect host cell and parasite nuclei. The Encephalitozoon species were unaffected in
germination by Lf up to a concentration of 2 mg/ml, or by bLfcin. However, bLf was able to
significantly diminish the infection to enterocytes.
4.4.2. Candida albicans
Besides microsporidia, numerous in vitro and in vivo studies have been conducted demon-
strating the potent capacity of Lf and derived peptides to inhibit the growth and infectivity
of other fungal pathogens that can affect mucous membrane of the upper digestive tract,
mouth, and pharynx, such as Candida albicans. Candida organisms commonly colonize the
human gastrointestinal tract as a component of the resident microbiota. Their presence is
generally benign. However, high-level colonization by Candida could delay healing of
inflammatory lesions and that inflammation promotes colonization. Both BID and gastroin-
testinal Candida colonization are associated with elevated levels of the proinflammatory
cytokine IL-17. Because Candida is a frequent colonizer, these effects have the potential to
impact many people [145]; in addition, C. albicans gut colonization in mice aggravates
inflammation in allergic and autoimmune diseases, not only in the gut but also in the extra-
gut tissues and underscores the necessity of investigating the pathogenic role of C. albicans
gut colonization in immune diseases in humans [146]. Since research about the effect of Lf
has been ample in Candida, it could be interesting to perform experiments to demonstrate
that Lf can help against both the gut inflammation and the pathogen. Despite not being an
intestinal pathogen, there is a work that reports the benefit of lactation of mice pups with
porcine Lf-rich milk against an oral infection with C. albicans [147]. Thus, treated CD1 mice
showed lower bacterial counts when compared with normal fed controls as well as a health-
ier architecture in the small intestine [148], suggesting that porcine Lf can be used as a
selective decontamination of the digestive tract regimen.
4.5. Toxoplasma gondii
Toxoplasma gondii is an obligatory deadly intracellular parasitic protozoan transmitted by
ingestion of uncooked infected meat; this parasite resides in every nucleated cell causing
severe complications in immunocompromised hosts. Tanaka et al. [149] examined the effect
of bovine Lfcin (LFcin-B), a peptide composed of 25 amino acid residues, on the viability
and infectivity of T. gondii parasites, both in vitro and in vivo. After treatment of T. gondii
with Lfcin at 100 μg/ml for 1 h, 65% of the parasites became oval in shape and had lost the
ability to exclude the trypan blue dye, a vital staining. Interestingly, approximately 96% of
the parasites treated with Lfcin at 1000 μg/ml for 0.5 h lost the dye exclusion ability. In
contrast, more than 80% of the parasites incubated with bLf or a C-terminal peptide at 1000
μg/ml for 4 h retained the dye exclusion ability. On the other hand, the loss of infectivity of
the parasites and/or cystozoites in cyst was confirmed by inoculation of mice. Five mice
inoculated with 102 untreated parasites died within 9 days post challenge. Similarly,
Lactoferrin in the Battle against Intestinal Parasites: A Review
http://dx.doi.org/10.5772/66819
167
parasites pretreated with bLf at 1000 μg/ml caused 100% mortality of inoculated mice
within 9 days post challenge. In contrast, four of five mice inoculated with the same dose
of parasites pretreated with Lfcin at 1000 μg/ml survived for more than 30 days post
challenge. In the case of parasites pretreated with Lfcin at 100 μg/ml, one of five mice
survived up to 30 days post challenge. In conclusion, this Lfcin peptide derived from bLf
could be used against human toxoplasmosis. To study the effector pathway of Toxoplasma
growth inhibitory activity induced by bLf in murine macrophage, the role of reactive
oxygen intermediates (O2−) and inorganic nitric oxide (NO) was examined by Tanaka et al.
[150]. Production of O2− was diminished in cultures of macrophages supplemented with bLf
and the effect was dose and time dependent. Production of NO was enhanced in cultures of
peritoneal macrophages supplemented with interferon-gamma, but not with bLf. Their
findings suggested that this Toxoplasma growth-inhibitory activity induced by bLf in mac-
rophages is not mediated by O2− or NO molecules; it may be mediated by an L-arginine-
dependent effector pathway that does not involve NO production. The same group of work
[151] administered orally or intraperitoneally bLfcin (5 and 0.1 mg/mouse, respectively).
Afterward, the researchers challenged mice with cysts of T. gondii at a dose of LD90.
Although only a small number of mice were used, both administration routes of Lfcin
prevented the death in the 100% mice.
Lf also has shown antimicrobial properties in its nanoformulation using alginate chitosan
calcium phosphate bLf nanocapsules (AEC-CCo-CP-bLf-NCs). Anand et al. [152] analyzed
and compared the effect of bLf in its native as well as nanoformulation AEC-CCo-CP-bLf-NC
against coccidian parasite T. gondii. The J7741 macrophage cell line culture model showed a
significant increase in NO production and low parasitemia. In their in vivo BALB/c mice model,
after treatment with NCs substantially increased the bioavailability of the protein and showed
comparatively increased levels of reactive oxygen species, NO production, and Th1 cytokine
which helped in parasite clearance. Regarding to the mechanism of action of NCs, immunore-
activity analysis showed accumulation of Lf in macrophages of various visceral organs, which
are the site of parasite multiplication.
4.6. Helminths
Antipathogenic properties of camel milk have been investigated to substitute for drugs hence
overcome drug resistance. Recently, Alimi et al. [153] investigated the antihelminthic activity
of the chemical compounds of camel milk. In vitro, the antihelminthic effects of camel milk
against Haemonchus contortus (nematode) from sheep were ascertained by egg hatching and
wormmotility inhibition, in comparison to milks from cow, ewe, and goat, and to the reference
drug albendazole. Chemical compounds revealed that camel milk has higher contents of
protective protein Lf and vitamin C than other species’ milk; for example, the camel milk
contains sevenfold more Lf than the cow milk. Camel milk showed ovicidal activity at all
tested concentrations and completely inhibited egg hatching at concentrations close to 100
mg/ml (IC50 = 42.39 mg/ml). Also, camel milk revealed in vitro activity against adult parasites
in terms of the paralysis and/or death of the worms at different hours post-treatment. After 8 h
of exposure, camel milk induced 100% mortality at the highest tested concentration. In
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contrast, there was 82.3% immobility of worms in albendazole at 8 h postexposition. Bioactive
compounds such as Lf and vitamin C may be involved in such an effect.
5. High-scale production of lactoferrin
Lf is considered as a nutraceutical protein by certain countries. Because of its versatile properties
on health and the null toxicity to humans, Lf can be added to different foods and nutritional
supplements, in addition to be used in medicine as an immune modulator, antimicrobial,
antiviral, and anticarcinogenic, among other properties, some of them unknown so far. Since
the finding of the regulatory property of Lf, much research has been published about this
molecule; nowadays we can found almost 7500 references in Pubmed for this glycoprotein.
Currently, Lf is one of the most studied proteins in order to have it commercially available and
with full biological activity. Concerning this, Lf from different origins, mainly from human and
bovine, but also from camel, buffalo, and other animals, has been obtained from milk and
colostrum. To have a better quality and production of Lf, since 25 years ago Lf has been cloned
in different vectors and expressed overall in eukaryotic systems which can glycosylate it, such
as yeasts and fungi [154–156]. From these organisms, Lf has been highly purified as a recom-
binant protein and its biological role, mainly antibacterial, has been confirmed. In addition,
human Lf has been cloned in transgenic cows and plants [156–159]. Interestingly, recombinant
hLf expressed in cows enhanced systematic and intestinal immune responses in piglets, used
as a model of infants [160]. In addition, when researchers analyzed the composition of meat
from the offspring of hLF transgenic cows, which can express hLf protein in their mammary
gland, they did not found any abnormality on the meat nutrient composition of hLF bulls
[161]. Therefore, the ample use of Lf in the human health care is promissory.
Commercially available Lf is now offered by several companies for using in research, as a
food supplement, as antibacterial or to increase immunity to improving health. Mainly skim
milk and cheese whey that have not undergone rigorous heating can be sources of bLF.
Because Lf has a cationic nature, it has been purified by cation exchange chromatography in
bLF-supplying companies [162–164]. The Japanese Morinaga Milk Co. was the pioneer in
research and development of bLf and in the addition of this protein to milk formula and
other products are also in the use of Lf in clinical trials. Nowadays, there are numerous
patents of Lf from companies that produce Lf of high quality. As examples, those of Nestle
for infant memory and learning and promotion of brain maturation in children or another
one to be used as antidiarrhea; Fonterra and Tatua, from New Zealand; Pharming Group
from The Netherlands; Abial Biotech from Spain; Tatura-Bio from Australia, and NRL-
Pharma from Japan, which produces enteric-coating Lf for use in adults in who the whole
Lf molecule can rise the intestine. Highly purified Lf without LPS is produced by Taradon
Laboratory. On the other hand, recombinant hLF for use in animal and human clinical
studies has been produced in the fungus Aspergillus niger var. awamori by Agennix Inc., for
the potential treatment of cancers, asthma, and chronic wounds; in transgenic cows by
Pharming Technologies N.V. as a nutraceutical; and in rice by Ventria Bioscience for diar-
rhea and iron deficiency [164].
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6. Conclusion and perspectives
Lf and its derived peptides Lfcins could be an option in the treatment of intestinal parasitic
diseases, based mainly on results in vitro and in animal models. Research in this glycopro-
tein has generally been leaded with success, although it is necessary to deep in the under-
standing of the mechanisms of action of Lf against parasites. In general, drugs used in the
therapy antiparasites cause toxic side effects, and/or the parasites can become resistant to
them. Lf is an innocuous protein that could be used as adjunct with drugs, with the
considerable advantage of using low doses of drugs due to the synergic effect of Lf. It
would be required more studies in animal models and carry out strict clinical trials with
methodologic accuracy and a large number of patients, in order to extend the use of Lf as a
parasiticide.
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